JP7765088B2 - Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 - Google Patents
Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物Info
- Publication number
- JP7765088B2 JP7765088B2 JP2022532865A JP2022532865A JP7765088B2 JP 7765088 B2 JP7765088 B2 JP 7765088B2 JP 2022532865 A JP2022532865 A JP 2022532865A JP 2022532865 A JP2022532865 A JP 2022532865A JP 7765088 B2 JP7765088 B2 JP 7765088B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- indol
- oxo
- carboxamide
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025175449A JP2026027269A (ja) | 2019-12-02 | 2025-10-17 | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1917603.1A GB201917603D0 (en) | 2019-12-02 | 2019-12-02 | Inhibitory compounds |
| GB1917603.1 | 2019-12-02 | ||
| GBGB2015692.3A GB202015692D0 (en) | 2020-10-02 | 2020-10-02 | Inhibitory compounds |
| GB2015692.3 | 2020-10-02 | ||
| GB2015820.0 | 2020-10-06 | ||
| GBGB2015820.0A GB202015820D0 (en) | 2020-10-06 | 2020-10-06 | Inhibitory compounds |
| PCT/GB2020/053081 WO2021111124A1 (en) | 2019-12-02 | 2020-12-01 | Polyheterocyclic compounds as mettl3 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025175449A Division JP2026027269A (ja) | 2019-12-02 | 2025-10-17 | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023506147A JP2023506147A (ja) | 2023-02-15 |
| JP2023506147A5 JP2023506147A5 (https=) | 2023-12-07 |
| JPWO2021111124A5 JPWO2021111124A5 (https=) | 2023-12-07 |
| JP7765088B2 true JP7765088B2 (ja) | 2025-11-06 |
Family
ID=73854829
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022532865A Active JP7765088B2 (ja) | 2019-12-02 | 2020-12-01 | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
| JP2025175449A Pending JP2026027269A (ja) | 2019-12-02 | 2025-10-17 | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025175449A Pending JP2026027269A (ja) | 2019-12-02 | 2025-10-17 | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12195458B2 (https=) |
| EP (1) | EP4069694A1 (https=) |
| JP (2) | JP7765088B2 (https=) |
| KR (1) | KR20220113431A (https=) |
| CN (1) | CN115151540A (https=) |
| AU (1) | AU2020394867A1 (https=) |
| BR (1) | BR112022010561A2 (https=) |
| CA (1) | CA3162166A1 (https=) |
| IL (1) | IL293340A (https=) |
| MX (1) | MX2022006700A (https=) |
| WO (1) | WO2021111124A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113905787A (zh) * | 2019-04-05 | 2022-01-07 | 斯托姆治疗有限公司 | Mettl3抑制化合物 |
| IL293340A (en) | 2019-12-02 | 2022-07-01 | Storm Therapeutics Ltd | Polyheterocyclic compounds as mettl3 inhibitors |
| US20230391770A1 (en) * | 2020-10-06 | 2023-12-07 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
| GB202107905D0 (en) * | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Processes for the preparation of inhibitory compounds |
| GB202107907D0 (en) * | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
| CN115894447B (zh) * | 2021-09-22 | 2024-10-01 | 成都先导药物开发股份有限公司 | Mettl3抑制剂及其用途 |
| CN116514805A (zh) * | 2021-12-10 | 2023-08-01 | 成都先导药物开发股份有限公司 | Mettl3抑制剂化合物 |
| WO2023129933A2 (en) * | 2021-12-29 | 2023-07-06 | 858 Therapeutics, Inc. | 6,6-fused heterocyclic compounds as mettl3 inhibitors |
| US20250145627A1 (en) | 2022-02-11 | 2025-05-08 | Xizang Haisco Pharmaceutical Co., Ltd. | METTL3 Inhibitor and Composition, and Application of Same in Medicine |
| WO2023235756A1 (en) * | 2022-05-31 | 2023-12-07 | The Trustees Of The University Of Pennsylvania | Compounds for the treatment of hiv |
| JP2025530847A (ja) * | 2022-09-16 | 2025-09-17 | 北京華益健康薬物研究中心 | Ｍｅｔｔｌ３阻害剤化合物、その医薬組成物及び用途 |
| GB202218672D0 (en) | 2022-12-12 | 2023-01-25 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2024153775A1 (en) | 2023-01-20 | 2024-07-25 | Epics Therapeutics | Piperidine derivatives as mettl3 inhibitors |
| WO2024200835A1 (en) | 2023-03-30 | 2024-10-03 | Novalix | Novel mettl3 inhibitors and use thereof in therapy |
| CN119899188A (zh) * | 2023-10-26 | 2025-04-29 | 杭州邦顺制药有限公司 | Mettl3抑制剂 |
| GB202316595D0 (en) | 2023-10-30 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| GB202316683D0 (en) | 2023-10-31 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2025242921A1 (en) | 2024-05-23 | 2025-11-27 | Storm Therapeutics Limited | Processes for the preparation of inhibitory compounds |
| CN121735955A (zh) * | 2024-09-25 | 2026-03-27 | 中国科学院上海药物研究所 | 稠合双环类化合物及其制备方法、组合物和应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007048070A2 (en) | 2005-10-21 | 2007-04-26 | Amgen Inc. | Pyrrolo-pyridine derivatives for the treatment of cancer diseases |
| WO2010074101A1 (ja) | 2008-12-25 | 2010-07-01 | 住友化学株式会社 | アミノピリジン化合物及びその用途 |
| WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
| JP2011516598A (ja) | 2008-04-17 | 2011-05-26 | グラクソ グループ リミテッド | ニコチン性アセチルコリン受容体サブタイプアルファ−７１のモジュレータとしてのインドール |
| JP2011522818A (ja) | 2008-06-06 | 2011-08-04 | アボット・ラボラトリーズ | 新規１，２，４オキサジアゾール化合物およびこれらの使用方法 |
| JP2012503627A (ja) | 2008-09-25 | 2012-02-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗炎症剤としての１ｈ−ベンズイミダゾール−５−カルボキサミド |
| WO2014063199A1 (en) | 2012-10-26 | 2014-05-01 | Akaal Pharma Pty Ltd | Organic compounds |
| WO2019197024A1 (en) | 2018-04-11 | 2019-10-17 | Chemestmed Ltd. | A method of modulating the rna methylation |
| JP2022528562A (ja) | 2019-04-05 | 2022-06-14 | ストーム・セラピューティクス・リミテッド | Ｍｅｔｔｌ３阻害化合物 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753664A (en) * | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
| FR2734814B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| US5928323A (en) | 1996-05-30 | 1999-07-27 | Sun Microsystems, Inc. | Apparatus and method for dynamically generating information with server-side software objects |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP0966461A1 (en) | 1997-03-21 | 1999-12-29 | Novartis AG | Pyrazole derivatives as herbicides |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1492874A (zh) | 2000-12-21 | 2004-04-28 | 大环内酯 | |
| IL157412A0 (en) | 2001-02-16 | 2004-03-28 | Aventis Pharmaceuticals Inc Av | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| US7169795B2 (en) | 2003-09-30 | 2007-01-30 | Bristol Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| KR20070010151A (ko) | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
| WO2006138549A1 (en) | 2005-06-17 | 2006-12-28 | Wyeth | Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists |
| CA2622639C (en) | 2005-10-04 | 2012-01-03 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | Hiv integrase inhibitors |
| KR20080064173A (ko) | 2005-10-21 | 2008-07-08 | 글락소 그룹 리미티드 | 항균제로서 유용한 페리 축합 트리시클릭 화합물 |
| CN102633783A (zh) * | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| CA2656825C (en) | 2006-06-22 | 2013-12-10 | Prana Biotechnology Limited | Method of treatment and agents useful for same |
| WO2008016666A2 (en) | 2006-08-02 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US8202524B2 (en) * | 2006-08-31 | 2012-06-19 | Sk Chemicals Co., Ltd. | Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby |
| WO2008074068A1 (en) | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| KR20090097194A (ko) | 2006-12-22 | 2009-09-15 | 아벡사 리미티드 | 바이사이클 피리미디논 및 그 용도 |
| CN101636398A (zh) * | 2007-02-05 | 2010-01-27 | 泽农医药公司 | 用于治疗钠通道介导的疾病或疾病状态的吡啶并嘧啶酮化合物 |
| WO2008100448A2 (en) | 2007-02-13 | 2008-08-21 | Helsinn Therapeutics (U.S.), Inc. | Method of treating cell proliferative disorders using growth hormone secretagogues |
| CN101801965B (zh) | 2007-08-17 | 2014-07-30 | 株式会社Lg生命科学 | 作为细胞坏死抑制剂的吲哚化合物 |
| KR20100124272A (ko) | 2008-02-07 | 2010-11-26 | 아보트 러보러터리즈 | 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법 |
| JP5539978B2 (ja) | 2008-07-02 | 2014-07-02 | アベキサ・リミテッド | チアゾピリミジノンおよびその使用 |
| EP2291377B1 (en) | 2008-07-02 | 2015-02-18 | Avexa Limited | Imidazopyrimidinones and uses thereof |
| CN102143962B (zh) | 2008-07-02 | 2015-03-11 | 爱维艾珂瑟有限公司 | 具有抗病毒特性的化合物 |
| CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| WO2010114898A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| CN102336751A (zh) | 2010-07-16 | 2012-02-01 | 爱维艾珂瑟有限公司 | 新型抗病毒剂 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| TW201245185A (en) | 2011-04-01 | 2012-11-16 | Lundbeck & Co As H | New positive allosteric modulators of nicotinic acetylcholine receptor |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2977464A4 (en) | 2013-03-19 | 2016-10-19 | Toppan Printing Co Ltd | PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| BR112016029825B1 (pt) | 2014-06-17 | 2020-10-27 | Cisen Pharmaceutical Co., Ltd. | composto |
| AU2015276699B2 (en) | 2014-06-17 | 2019-10-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor |
| JP6546654B2 (ja) | 2014-08-22 | 2019-07-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 淋菌感染を治療するための三環式含窒素化合物 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| WO2017070464A1 (en) * | 2015-10-22 | 2017-04-27 | Memorial Sloan-Kettering Cancer Center | Cofactor analogs as methyltransferase inhibitors for treating cancer |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10730903B2 (en) * | 2016-09-19 | 2020-08-04 | Memorial Sloan-Kettering Cancer Center | Adenosine analogs as methyltransferase inhibitors for treating cancer |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| MX390512B (es) | 2017-03-26 | 2025-03-20 | Takeda Pharmaceuticals Co | Carboxamidas heteroaromáticas sustituidas con piperidinilo y piperazinilo como moduladores de gpr6. |
| CN107349217B (zh) * | 2017-07-21 | 2020-06-09 | 深圳大学 | 一种基于mettl3的小干扰rna及其药物和应用 |
| CN112585119A (zh) | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| SG11202105325QA (en) | 2018-11-30 | 2021-06-29 | Epizyme Inc | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
| IL293340A (en) | 2019-12-02 | 2022-07-01 | Storm Therapeutics Ltd | Polyheterocyclic compounds as mettl3 inhibitors |
-
2020
- 2020-12-01 IL IL293340A patent/IL293340A/en unknown
- 2020-12-01 BR BR112022010561A patent/BR112022010561A2/pt unknown
- 2020-12-01 AU AU2020394867A patent/AU2020394867A1/en active Pending
- 2020-12-01 MX MX2022006700A patent/MX2022006700A/es unknown
- 2020-12-01 WO PCT/GB2020/053081 patent/WO2021111124A1/en not_active Ceased
- 2020-12-01 EP EP20825189.2A patent/EP4069694A1/en active Pending
- 2020-12-01 CN CN202080095149.6A patent/CN115151540A/zh active Pending
- 2020-12-01 US US17/778,701 patent/US12195458B2/en active Active
- 2020-12-01 KR KR1020227022463A patent/KR20220113431A/ko active Pending
- 2020-12-01 CA CA3162166A patent/CA3162166A1/en active Pending
- 2020-12-01 JP JP2022532865A patent/JP7765088B2/ja active Active
-
2022
- 2022-07-29 US US17/876,938 patent/US11725010B2/en active Active
-
2024
- 2024-11-01 US US18/934,945 patent/US20250122195A1/en active Pending
-
2025
- 2025-10-17 JP JP2025175449A patent/JP2026027269A/ja active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007048070A2 (en) | 2005-10-21 | 2007-04-26 | Amgen Inc. | Pyrrolo-pyridine derivatives for the treatment of cancer diseases |
| JP2011516598A (ja) | 2008-04-17 | 2011-05-26 | グラクソ グループ リミテッド | ニコチン性アセチルコリン受容体サブタイプアルファ−７１のモジュレータとしてのインドール |
| JP2011522818A (ja) | 2008-06-06 | 2011-08-04 | アボット・ラボラトリーズ | 新規１，２，４オキサジアゾール化合物およびこれらの使用方法 |
| JP2012503627A (ja) | 2008-09-25 | 2012-02-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗炎症剤としての１ｈ−ベンズイミダゾール−５−カルボキサミド |
| WO2010074101A1 (ja) | 2008-12-25 | 2010-07-01 | 住友化学株式会社 | アミノピリジン化合物及びその用途 |
| WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
| WO2014063199A1 (en) | 2012-10-26 | 2014-05-01 | Akaal Pharma Pty Ltd | Organic compounds |
| WO2019197024A1 (en) | 2018-04-11 | 2019-10-17 | Chemestmed Ltd. | A method of modulating the rna methylation |
| JP2022528562A (ja) | 2019-04-05 | 2022-06-14 | ストーム・セラピューティクス・リミテッド | Ｍｅｔｔｌ３阻害化合物 |
Non-Patent Citations (2)
| Title |
|---|
| Celeste Alverez et al.，Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway，ACS Med. Chem. Lett.，2016年，2016, 7，182-187，DOI: 10.1021/acsmedchemlett.5b00396 |
| Moses Moustakim et al.，Discovery of an MLLT1/3 YEATS Domain Chemical Probe，Angewandte Chemie, International Edition，57(50)，2018年，16302-16307，DOI: 10.1002/anie.201810617 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022010561A2 (pt) | 2022-11-16 |
| JP2023506147A (ja) | 2023-02-15 |
| MX2022006700A (es) | 2022-09-02 |
| KR20220113431A (ko) | 2022-08-12 |
| AU2020394867A1 (en) | 2022-05-26 |
| JP2026027269A (ja) | 2026-02-18 |
| US20230116403A1 (en) | 2023-04-13 |
| US12195458B2 (en) | 2025-01-14 |
| CN115151540A (zh) | 2022-10-04 |
| US11725010B2 (en) | 2023-08-15 |
| IL293340A (en) | 2022-07-01 |
| CA3162166A1 (en) | 2021-06-10 |
| US20230002378A1 (en) | 2023-01-05 |
| EP4069694A1 (en) | 2022-10-12 |
| WO2021111124A1 (en) | 2021-06-10 |
| US20250122195A1 (en) | 2025-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7765088B2 (ja) | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 | |
| JP7762957B2 (ja) | Ｍｅｔｔｌ３阻害化合物 | |
| JP7534379B2 (ja) | ベンズイミダゾロン由来のｂｃｌ６阻害剤 | |
| US9371319B2 (en) | Pyrrolopyridineamino derivatives as MPS1 inhibitors | |
| US20250236624A1 (en) | Heterocyclic Compounds as RET Kinase Inhibitors | |
| EP3630749B9 (en) | 2-quinolone derived inhibitors of bcl6 | |
| JP6297570B2 (ja) | 薬理活性化合物 | |
| CN106459035B (zh) | N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途 | |
| EP3596073A1 (en) | Tricyclic compounds for use in treatment of proliferative disorders | |
| WO2022074379A1 (en) | Mettl3 inhibitory compounds | |
| EP2935272A1 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | |
| WO2022074391A1 (en) | Compounds inhibitors of mettl3 | |
| WO2024126987A1 (en) | Inhibitory compounds | |
| RU2858287C2 (ru) | Полигетероциклические соединения в качестве ингибиторов mettl3 | |
| AU2010213014A1 (en) | 2-morpholino-pyrido[3,2-d]pyrimidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241031 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250411 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250805 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250819 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250916 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251017 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7765088 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |